ProMab Biotechnologies Signs Worldwide License Agreement with NantKwest to Develop Ab for Multiple Myeloma

Shots:

• ProMab Biotechnologies signs WW license agreement with NantKwest to develop Ab targeting B-Cell Maturation Antigen (BCMA) against myeloma

• ProMab Biotechnologies get an option to add five chimeric antigen receptor (CAR) targeting sequences based on natural killer (NK) cell therapies

• NantKwest’s lead NK cell platform includes haNK and taNK designed to induce cell death by innate, antibody-mediated, and CAR directed killing against cancer and virally induced infectious diseases

Click here to read full press release/ article | Ref: Nantkwest | Image: Nantkwest